Key result
Thrombelastogram-guided medication adjustment significantly reduced the 3-month incidence of major adverse cardiovascular events to 5.77% compared to 25.25% with routine care.
Why the study?
The study investigated the effects of thrombelastogram-guided clopidogrel and aspirin on major adverse cardiovascular events in patients following percutaneous coronary intervention.
Does TEG-guided dose adjustment of clopidogrel and aspirin reduce MACE and bleeding events in patients with coronary heart disease after PCI?
Cohort (n=203)
No
Does TEG-guided dose adjustment of clopidogrel and aspirin reduce MACE and bleeding events in patients with coronary heart disease after PCI?
Answers are grounded in this paper and cite their sources.
TEG-guided dose adjustment of clopidogrel and aspirin significantly reduces the incidence of MACE and bleeding events in patients with coronary heart disease after PCI compared to routine dosing.
Effects of thrombelastogram-guided (TEG-guided) clopidogrel and aspirin on major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) were investigated. A retrospective analysis was performed on 203 patients undergoing PCI interventional therapy in the Cardiovascular Medicine of Weihai Central Hospital from February 2015 to September 2016. The patients were treated with clopidogrel and aspirin for anti-thrombus therapy. Among them, 104 patients who had TEG detection of anticoagulant effects for guiding medication were the experimental group, and 99 patients without TEG detection for guiding medication the control group. The coagulation function and the platelet inhibition rate of patients after medication were evaluated and compared between the two groups. The incidence of MACE and bleeding events of patients was counted during three months of follow-up. Patients in the experimental group had higher R (coagulation reaction time) value and K (blood clot formation time) value than those in the control group after treatment (P<0.05), and lower MA (maximum amplitude) value than those in the control group (P<0.05). Patients in the experimental group had higher postoperative platelet inhibition rate than those in the control group (P<0.05). Patients in the experimental group had lower incidence of MACE and bleeding events than those in the control group (P<0.05). Coronary heart disease (CHD) patients after PCI with the TEG-guided dose adjustment of clopidogrel have more satisfactory treatment effects than patients without the TEG guidance. TEG makes the treatment of patients more targeted and is worthy of promotion.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) conducted a cohort in Coronary heart disease after percutaneous coronary intervention (n=203). Thrombelastogram-guided (TEG-guided) medication adjustment vs. Routine medication without TEG guidance was evaluated on Incidence of major adverse cardiovascular events (MACE) (p=<0.001). Thrombelastogram-guided medication adjustment significantly reduced the 3-month incidence of major adverse cardiovascular events to 5.77% compared to 25.25% with routine care.
Synapse has enriched 10 related papers. Consider them for comparative context: